Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1532-1539

  Jarvis, Courtney I ^a   Cabrera, Adriana ^a   Charron, Derek ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

alogliptin; dipeptidyl peptidase 4 inhibitor; Kazano; Nesina; Oseni; SYR 332; type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALOGLIPTIN PLUS METFORMIN; ALOGLIPTIN PLUS PIOGLITAZONE; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; METFORMIN PLUS PIOGLITAZONE; PIOGLITAZONE;

AREA UNDER THE CURVE; BODY WEIGHT; CARDIOVASCULAR DISEASE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; EMBASE; ENZYME INACTIVATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; MEAL; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE;

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; KAZANO; NESINA; OSENI; SYR-332; TYPE 2 DIABETES MELLITUS;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; TREATMENT OUTCOME; URACIL;

EID: 84889043453     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013504076     Document Type: Review

References (26)

1. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011:.
2. Diagnosis and classification of diabetes mellitus.Diabetes Care. 2013;36:S67-S74.
3. Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2012;35:1364-1379.
4. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013:.
5. Takeda Pharmaceutical Company Limited. Takeda initiates cardiovascular outcomes trial for alogliptin, an investigational treatment for type 2 diabetes. http://www.takeda.com/news/2009/20090828_3721.html. Accessed August 12, 2013.
6. White WB,Bakris GL,Bergenstral RM,et al.Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes.Am Heart J. 2011;162:620.e1-626.e1.
7. US Food and Drug Administration. FDA approves three new drug treatments for type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm. Accessed April 30, 2013.
8. Russell-Jones D,Gough S.Recent advances in incretin-based therapies.Clin Endocrinol (Oxf). 2012;77:489-499.
9. Christopher R,Covington P,Davenport M,Fleck P,Karim A.Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.Clin Ther. 2008;30:513-527.
10. Covington P,Christopher R,Davenport M,Fleck P,Karim A.Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.Clin Ther. 2008;30:499-512.
11. Karim A,Fleck P,Hetman L,et al.Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (abstract 538-P).Diabetes. 2008;57:A160.
12. Karim A,Fleck P,Dorsey D,Zhang W,Mekki Q,Preston RA.Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment (abstract 107).J Clin Pharmacol. 2007 1207;47:.
13. DeFronzo RA,Fleck PR,Wilson CA,Mekki Q.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.Diabetes Care. 2008;31:2315-2317.
14. Nauck MA,Ellis GC,Fleck PR,Wilson CA,Mekki Q.Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.Int J Clin Pract. 2009;63:46-55.
15. Seino Y,Miyata Y,Hiroi S,Hirayama M,Kaku K.Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.Diabetes Obes Metab. 2012;14:927-936.
16. Pratley R,Wilson C,Fleck P.Alogliptin plus metformin combination therapy vs. alogliptin or metformin monotherapy for type 2 diabetes mellitus [abstract 841].Diabetologia. 2012;55:S347-S348.
17. Pratley RE,Kipnes MS,Fleck PR,Wilson C,Mekki Q.Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.Diabetes Obes Metab. 2009;11:167-176.
18. Rosenstock J,Rendell MS,Gross JL,Fleck PR,Wilson CA,Mekki Q.Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia.Diabetes Obes Metab. 2009;11:1145-1152.
19. Pratley RE,Reusch JE,Fleck PR,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.Curr Med Res Opin. 2009;25:2361-2371.
20. Rosenstock J,Inzucchi SE,Seufert J,et al.Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.Diabetes Care. 2010;33:2406-2408.
21. Kaku K,Itayasu T,Hiroi S,et al.Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.Diabetes Obes Metab. 2011;13:1028-1035.
22. Bosi E,Ellis GC,Wilson CA,et al.Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.Diabetes Obes Metab. 2011;13:1088-1096.
23. DeFronzo RA,Burant CF,Fleck P,et al.Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type-2 diabetes.J Clin Endocrinol Metab. 2012;97:1615-1622.
24. White WB,Cannon CP,Heller SR,et al.Alogliptin after acute coronary syndrome in patients with type 2 diabetes mellitus.N Engl J Med. 2013;:.
25. White WB,Pratley R,Fleck P,et al.Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.Diabetes Obes Metab. 2013;5:668-673.
26. REDBOOK Online [Internet]. Greenwood Village, CO: Truven Health Analytics. http://www.micromedexsolutions.com. Accessed August 12, 2013.